🪣

CLiCK — 4% Tetrasodium EDTA for CVAD Complication Prevention

1. Publication

Title: 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications: A Randomized Clinical Trial
Acronym: CLiCK (Control of Line Complications with KiteLock)
Year & Journal: JAMA, published online May 18, 2026
Citation: Ornowska M, Wittmann J, Blitz S, et al. 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications: A Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.6025

2. Context & Rationale

Background: Central venous access devices (CVADs) are essential for delivering fluids, medications, antibiotics, and nutrition to most critical care patients, but are frequently complicated by bloodstream infections, catheter occlusion, and thrombosis. Standard catheter lock solutions (saline, citrate) do not have strong antimicrobial/antithrombotic properties; 4% tetrasodium EDTA (t-EDTA, commercial product KiteLock) is a non-antibiotic, antimicrobial and anticoagulant catheter lock formulated to reduce bacterial colonization/biofilm formation and maintain patency.

Research Question/Hypothesis: In adult ICU patients with CVADs, does a 4% t-EDTA locking solution reduce a composite of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase (thrombolysis), or catheter removal due to occlusion, compared with control locking fluid (saline or 4% citrate)?

Why This Matters: CVAD complications are common, costly, and prolong ICU/hospital stay; a simple, non-antibiotic catheter lock intervention (avoiding antimicrobial resistance concerns associated with antibiotic locks) could meaningfully reduce this burden at scale.

3. Design & Methods

Study Type: Multicenter, cluster-randomized, double-blinded, crossover trial
Setting & Centers: 6 sites, Canada (Burnaby Hospital, Nanaimo Regional General Hospital, Royal Columbian Hospital, Surrey Memorial Hospital, Royal Jubilee Hospital, St. Boniface Hospital)
Population:

Inclusion: Adult ICU patients with a central venous access device
Exclusions: Not detailed in available trial text

Intervention: 4% tetrasodium EDTA (t-EDTA) locking solution (KiteLock)
Comparator: Control locking fluid (saline or 4% citrate)
Design: Cluster-randomized, double-blinded, crossover (sites switch between intervention and control periods)
Blinding: Double-blinded
Statistical Power & Follow-Up: Primary outcome: composite incidence of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase, or catheter removal due to occlusion, expressed as events per 1,000 catheter-days.

4. Key Results

Outcome	4% t-EDTA	Control (Saline/Citrate)	Effect Size	Notes
Composite: bloodstream infection, occlusion requiring alteplase, or removal for occlusion (primary)	13.1 events/1,000 catheter-days	19.9 events/1,000 catheter-days	~32% relative reduction	Statistically significant reduction with t-EDTA

Note on data completeness: The exact statistical comparison (rate ratio with 95% CI and p-value) was not available in the accessible source text beyond the raw event rates and the ~32% relative reduction described in secondary reporting; readers should consult the primary JAMA publication for the full statistical inference.

5. Internal Validity Assessment

Randomization & Allocation: Cluster-randomized (by site), double-blinded, crossover design — a notably rigorous design for a catheter-lock intervention trial, with blinding meaningfully reducing both performance and detection bias.
Protocol Adherence & Separation: Crossover design allows each site to serve as its own control across periods, strengthening internal comparison; specific adherence details not available in accessible text.
Blinding & Detection Bias: Double-blinding is a genuine methodological strength, distinguishing this trial from many other device/solution-based ICU trials that are typically open-label.
Missing Data & Sensitivity Analyses: Not detailed in available trial text.
Overall Internal Validity Conclusion: Moderate-to-strong — the double-blinded, cluster-randomized crossover design is a notable methodological strength for this type of intervention, supporting good confidence in the observed effect; specific adherence, missing-data, and full statistical inference details were not accessible for this summary.

6. External Validity Assessment

Population Representativeness: Adult ICU patients with CVADs across 6 Canadian sites (British Columbia and Manitoba) — a relevant, common critical care population.
Practice Context: The intervention (a specific commercial locking solution, KiteLock, manufactured by trial funder SterileCare Inc.) requires adoption of a specific commercial product; industry funding/product provision is a relevant disclosure for interpreting the trial's context, though this does not itself invalidate the randomized, double-blinded design.
Overall External Validity Conclusion: Good for adult ICU CVAD populations in similar health systems; applicability requires adoption of the specific commercial t-EDTA product tested, which may have cost/availability implications outside the trial's home market.

7. Strengths & Limitations

Strengths:

Double-blinded design — uncommon rigor for a catheter-lock-solution trial
Cluster-randomized crossover design strengthens internal comparison
Addresses a common, costly, and clinically significant ICU complication (CVAD-associated bloodstream infection/occlusion)
Non-antibiotic mechanism avoids antimicrobial-resistance concerns associated with antibiotic catheter locks

Limitations:

Industry funding and investigational product provision (SterileCare Inc.) is a relevant conflict-of-interest consideration
Full statistical inference (rate ratio, CI, p-value) not accessible for this summary
Single-country (Canada) trial

8. Interpretation & Practice Impact

Clinical Implications: 4% t-EDTA locking solution significantly reduces a composite of CVAD-associated bloodstream infection, occlusion requiring thrombolysis, and occlusion-related catheter removal (13.1 vs 19.9 events/1,000 catheter-days, roughly a 32% relative reduction) — supporting consideration of this locking solution as an alternative to standard saline/citrate locks in ICU patients with central venous access devices.
Mechanistic Coherence: Consistent with t-EDTA's proposed dual mechanism (antimicrobial/anti-biofilm plus anticoagulant properties), addressing both major CVAD complication categories (infection and occlusion) simultaneously.
Systems-Level Takeaway: A simple, non-antibiotic catheter-care intervention with a rigorous (double-blinded) trial basis represents an appealing, easily implementable ICU quality-improvement target, avoiding antimicrobial stewardship concerns associated with antibiotic-based catheter locks.

9. Controversies & Subsequent Evidence

Editorial Commentary/Debates: Senior author Dr. Steven Reynolds directly stated the intervention "reduced the incidence of a composite endpoint of CVAD complications compared with saline or 4% citrate control group" when presenting at the American Thoracic Society International Conference (May 2026).
Guideline Integration: As a newly published, industry-supported trial, formal guideline incorporation is not yet established at time of this handbook's compilation; the double-blinded design strengthens the evidence base for potential future guideline consideration relative to typically open-label device/solution trials in this space.

10. Summary & Executive Takeaway

Summary: The CLiCK trial, a double-blinded, cluster-randomized crossover study across 6 Canadian ICUs, tested 4% tetrasodium EDTA catheter locking solution against standard saline/citrate locks in adult ICU patients with central venous access devices. The composite outcome (bloodstream infection, occlusion requiring alteplase, or occlusion-related removal) occurred at 13.1 vs 19.9 events per 1,000 catheter-days — an approximately 32% relative reduction with t-EDTA.

Overall Takeaway: A double-blinded, methodologically rigorous trial found that 4% tetrasodium EDTA catheter locking solution meaningfully reduces CVAD-associated complications (infection and occlusion combined) compared with standard locks — a promising, simple, non-antibiotic intervention for a common and costly ICU problem, though industry funding/product provision and incomplete access to full statistical inference are relevant considerations for this summary.

11. Bibliography

Ornowska M, Wong H, Ouyang Y, et al. Control of Line Complications with KiteLock (CLiCK) in the critical care unit: study protocol. Trials. 2022;23(1):719.